SPDR S&P Biotech ETF Rating $95.60 -1.08 (-1.12%) Closing price 09/19/2025 04:10 PM EasternExtended Trading$95.80 +0.21 (+0.21%) As of 09/19/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock SPDR S&P Biotech ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XBI Aggregate RatingModerate Buy 2.72Holdings in XBI have an aggregate rating of Moderate Buy based on 485 analyst ratings issued in the past year covering 25 companies (58.0% of the portfolio).XBI Aggregate Price Target$95.60High Prediction$95.60Average Prediction$95.60Low Prediction$95.60Holdings in XBI have an aggregate price target of $95.60 and a range of $95.60 to $95.60 covering 25 companies (58.0% of the portfolio).XBI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy4 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by SPDR S&P Biotech ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 XBI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings3.43%ALNYAlnylam Pharmaceuticals$453.56+0.3%3.8628 of 5 stars2.86$439.58 -3.1%28Trending NewsAnalyst Forecast3.25%INSMInsmed$144.76-0.8%3.0362 of 5 stars2.94$139.86 -3.4%17High Trading Volume3.20%UTHRUnited Therapeutics$417.57+1.9%4.6424 of 5 stars2.69$438.85 5.1%13Trending NewsInsider TradeHigh Trading Volume3.14%HALOHalozyme Therapeutics$77.81+1.5%4.5609 of 5 stars2.33$67.11 -13.8%12Positive NewsHigh Trading Volume2.73%INCYIncyte$86.53+0.6%4.7708 of 5 stars2.33$82.53 -4.6%18Trending NewsAnalyst ForecastHigh Trading Volume2.53%NBIXNeurocrine Biosciences$145.23-0.3%4.4862 of 5 stars2.85$160.26 10.4%20Positive NewsHigh Trading Volume2.51%ABBVAbbVie$222.29+0.1%4.7746 of 5 stars2.93$222.68 0.2%27Trending NewsAnalyst RevisionHigh Trading Volume2.45%MDGLMadrigal Pharmaceuticals$439.93-0.2%3.9452 of 5 stars2.90$483.38 9.9%10High Trading Volume2.44%BIIBBiogen$142.50-0.9%4.6762 of 5 stars2.32$181.65 27.5%31Positive NewsAnalyst DowngradeHigh Trading Volume2.39%REGNRegeneron Pharmaceuticals$591.99-1.1%4.793 of 5 stars2.82$817.67 38.1%28Positive NewsHigh Trading Volume2.35%GILDGilead Sciences$114.09+0.4%4.9445 of 5 stars2.89$117.17 2.7%28Positive NewsHigh Trading Volume2.35%BBIOBridgeBio Pharma$52.37-1.8%4.332 of 5 stars3.00$63.94 22.1%17High Trading Volume2.28%NTRANatera$181.11+0.7%3.0899 of 5 stars3.06$194.00 7.1%18Positive News2.20%EXASExact Sciences$53.32-0.5%4.7912 of 5 stars2.88$68.05 27.6%242.14%BMRNBioMarin Pharmaceutical$54.36-1.4%4.9778 of 5 stars2.64$92.60 70.3%22Positive NewsHigh Trading Volume2.12%AMGNAmgen$285.41+3.5%4.5563 of 5 stars2.24$304.43 6.7%21Positive NewsHigh Trading Volume2.11%IONSIonis Pharmaceuticals$61.01-1.2%3.8206 of 5 stars2.81$67.88 11.3%162.06%EXELExelixis$40.10-0.9%4.6511 of 5 stars2.61$44.42 10.8%23High Trading Volume2.05%CYTKCytokinetics$48.66-1.3%4.2412 of 5 stars2.87$75.38 54.9%15Trending News2.00%MRNAModerna$25.24-0.8%4.4676 of 5 stars2.05$41.81 65.7%221.93%ROIVRoivant Sciences$15.04-0.3%3.4353 of 5 stars3.00$19.94 32.6%9Trending NewsAnalyst Revision1.92%VRTXVertex Pharmaceuticals$383.12-1.0%4.9008 of 5 stars2.57$496.05 29.5%28Positive NewsAnalyst RevisionHigh Trading Volume1.61%RVMDRevolution Medicines$43.54-3.7%4.28 of 5 stars3.07$73.67 69.2%15Trending News1.45%CRSPCRISPR Therapeutics$62.32-1.0%2.9274 of 5 stars2.50$71.50 14.7%18High Trading Volume1.39%TGTXTG Therapeutics$32.37-0.7%4.29 of 5 stars2.80$48.00 48.3%5Trending NewsAnalyst Revision This page (NYSEARCA:XBI) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
